{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:40:14Z","timestamp":1759974014699,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"11-12","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.medmal.2006.05.009","type":"journal-article","created":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T12:19:10Z","timestamp":1154434750000},"page":"650-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pneumonies aigu\u00ebs communautaires\u00a0: analyse critique des\u00a0essais cliniques"],"prefix":"10.1016","volume":"36","author":[{"given":"C.","family":"Chidiac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2006.05.009_bib1","doi-asserted-by":"crossref","unstructured":"Anonyme. IVe conf\u00e9ence de consnsus en th\u00e9rapeutiqueanti-infectieuse de la SPILF\u00a0: Les infections des voies respiratoires 18 octobre 1991, Lille. ed Mal. Inf. 1992\u00a0; 22, Suppl\u00e9ment 2\u00a0: 43\u20136.","DOI":"10.1016\/S0399-077X(05)81448-9"},{"key":"10.1016\/j.medmal.2006.05.009_bib2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0399-077X(05)80324-5","article-title":"Recommandations sur la prise en charge de la pathologie infectieuse respiratoire","volume":"25","author":"Mouton","year":"1995","journal-title":"Med. Mal. Inf."},{"key":"10.1016\/j.medmal.2006.05.009_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0399-077X(01)00230-X","article-title":"R\u00e9vision de la IVe conf\u00e9rence de consensus en th\u00e9rapeutique anti-infectieuse de la Soci\u00e9t\u00e9 de pathologie infectieuse de langue fran\u00e7aise (SPILF)","volume":"31","year":"2001","journal-title":"Med Mal Inf"},{"key":"10.1016\/j.medmal.2006.05.009_bib4","first-page":"125","article-title":"Antibioth\u00e9rapie par voie g\u00e9n\u00e9rale en pratique courante\u00a0: infections respiratoires basses de l'adulte","volume":"32","year":"2002","journal-title":"Med. Mal. Inf."},{"key":"10.1016\/j.medmal.2006.05.009_bib5","doi-asserted-by":"crossref","unstructured":"Afssaps. Antibioth\u00e9rapie par voie g\u00e9n\u00e9rale en pratique courante infections respiratoires basses de l'adulte et de l'enfant (actualisation novembre 2005). Antibioth\u00e9rapie par voie g\u00e9n\u00e9rale en pratique courante au cours des infections respiratoires basses de l'adulte et de l'enfant. Med. Mal. Inf. 2005; 35\u00a0: 619\u201334. http:\/\/afssaps.sante.fr\/htm\/5\/rbp\/indantib.htm.","DOI":"10.1016\/j.medmal.2005.11.002"},{"issue":"sp\u00e9cial","key":"10.1016\/j.medmal.2006.05.009_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0399-077X(05)81468-4","article-title":"Traitement des pneumonies suppos\u00e9es \u00e0 germes extracellulaires\u00a0: analyse critique des essais","volume":"22","author":"Beaucaire","year":"1992","journal-title":"Med. Mal. Inf."},{"key":"10.1016\/j.medmal.2006.05.009_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0399-077X(01)00181-0","article-title":"Traitement antibiotique des pneumonies communautaires de l'adulte\u2013apport des nouvelles mol\u00e9cules\u00a0; place des traitements de dur\u00e9e abr\u00e9g\u00e9e\u00a0; donn\u00e9es pharmaco\u00e9conomiques","volume":"31","author":"Garr\u00e9","year":"2001","journal-title":"Med. Mal. Inf."},{"key":"10.1016\/j.medmal.2006.05.009_bib8","unstructured":"Anaes. Guide d'analyse de la litt\u00e9rature et gradation des recommandations. Janvier 2000 http:\/\/www.anaes.fr\/anaes\/anaesparametrage.nsf\/Page?ReadForm&Section=\/anaes\/Rechercher.nsf\/Rechercher?OpenAgent&Fuzzy=c&query=analyse+and+article&sectrec=all."},{"key":"10.1016\/j.medmal.2006.05.009_bib9","unstructured":"Committee for Proprietary Medical Products. Note for guidance on statistical principles for clinical trials (1997). European Agency for the Evaluation of Medical Products. http:\/\/www.eudra.org\/emea.html."},{"key":"10.1016\/j.medmal.2006.05.009_bib10","unstructured":"Food and Drug Administration. Guidance for industry. Developing antimicrobial drugs. G\u00e9n\u00e9ral consid\u00e9rations for clinical trials (1997). http:\/\/www.fda.gov\/cder\/guidance\/index.htm."},{"key":"10.1016\/j.medmal.2006.05.009_bib11","unstructured":"Food and Drug Administration. Guidance for industry. Community-acquired pneumonia\u2013developing antimicrobial drugs for treatment (1998). http:\/\/www.fda.gov\/cder\/guidance\/index.htm."},{"issue":"suppl 1","key":"10.1016\/j.medmal.2006.05.009_bib12","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/clind\/15.Supplement_1.S62","article-title":"Evaluation of new anti-infective drugs for the treatment of respiratory tract infection","volume":"15","author":"Chow","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine Fine","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.medmal.2006.05.009_bib14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.medmal.2006.05.009_bib15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.116.4.974","article-title":"A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia","volume":"116","author":"Moola","year":"1999","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.medmal.2006.05.009_bib16","first-page":"243","article-title":"Multicenter randomized trial comparing MER (1,5\u00a0g daily) and imipenem\/cilastatin (2\u00a0g daily) in the hospital treatment of community-acquired pneumonia","volume":"25","author":"Bartoloni","year":"1999","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.medmal.2006.05.009_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000029424","article-title":"Treatment of community-acquired pneumonia in outpatients\u00a0:randomized study of clarithromycin alone versus clarithromycin and cefuroxime","volume":"66","author":"Rovira","year":"1999","journal-title":"Respiration (Herrlisheim)"},{"issue":"1","key":"10.1016\/j.medmal.2006.05.009_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/48.1.67","article-title":"049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin","volume":"48","author":"File","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.05.009_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0149-2918(02)85136-0","article-title":"A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia","volume":"24","author":"Sokol","year":"2002","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.medmal.2006.05.009_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with t\u00e9lithromycine compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.medmal.2006.05.009_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2004.01.011","article-title":"Azithromycin versus comparative therapy for the treatment of community acquired pneumonia","volume":"24","author":"Rahav","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"160","key":"10.1016\/j.medmal.2006.05.009_bib22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archinte.160.9.1294","article-title":"Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial","volume":"8","author":"Vergis","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.medmal.2006.05.009_bib23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1469-0691.1999.tb00705.x","article-title":"Comparaive study of l\u00e9vofloxacine and amoxycillin\/clavulanic acid in adults with mil-to-moderate community-acquired pneumonia","volume":"5","author":"Carbon","year":"1999","journal-title":"Clin. Microbiol. Infect."},{"issue":"6","key":"10.1016\/j.medmal.2006.05.009_bib24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/AAC.46.6.1746-1754.2002","article-title":"Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment","volume":"46","author":"Finch","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.medmal.2006.05.009_bib25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/jac\/dkg458","article-title":"557 Clinical Study Group. Oral pharmacokinetically enhanced co-amoxiclav 2000\/125 mg, twice daily, compared with co-amoxiclav 875\/125\u00a0mg, three times daily, in the treatment of community-acquired pneumonia in European adults","volume":"52","author":"Garau","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.medmal.2006.05.009_bib26","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/AAC.48.9.3323-3331.2004","volume":"48","author":"File","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medmal.2006.05.009_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00044011-200323080-00001","article-title":"Comparison of clarithromycin and amoxicillin\/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae","volume":"23","author":"Bonvehi","year":"2003","journal-title":"Clin Drug Invest"},{"issue":"7","key":"10.1016\/j.medmal.2006.05.009_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.medmal.2006.05.009_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0924-8579(02)00126-7","article-title":"The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000\/125\u00a0mg, twice daily, versus oral amoxycillin\u2013clavulanate 1000\/125\u00a0mg, three times daily, for the treatment of bacterial community\u2013acquired pneumonia in adults","volume":"20","author":"Petitpretz","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.medmal.2006.05.009_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.03.00045202","article-title":"Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia","volume":"21","author":"Torres","year":"2003","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.medmal.2006.05.009_bib31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0149-2918(02)80078-9","article-title":"Protocol 020 Study Group. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia","volume":"24","author":"Vetter","year":"2002","journal-title":"Clin. Ther."},{"issue":"34","key":"10.1016\/j.medmal.2006.05.009_bib32","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/339543","article-title":"A study evaluating the efficacy, safety, and tolerability of ertapenem vs ceftriaxone for the treatment of community-acquired pneumonia in adults","volume":"15","author":"Ortiz-Ruiz","year":"2002","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.medmal.2006.05.009_bib33","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1046\/j.1532-5415.2003.51507.x","article-title":"Ertapenem therapy for community-acquired pneumonia in the elderly","volume":"51","author":"Woods","year":"2003","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.medmal.2006.05.009_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/498149","article-title":"Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy","volume":"41","author":"Welte","year":"2005","journal-title":"Clinical Infect. Dis."},{"issue":"11","key":"10.1016\/j.medmal.2006.05.009_bib35","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0149-2918(02)80088-1","volume":"24","author":"Lode","year":"2002","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/j.medmal.2006.05.009_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7\u00a0days compared to amoxicillin\/clavulanic acid thrice daily for 10\u00a0days for the treatment of community-acquired pneumonia of suspected pneumococcal origin","volume":"98","author":"Leophonte","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.medmal.2006.05.009_bib37","doi-asserted-by":"crossref","unstructured":"Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther. 2002;24(8):1292-308. Erratum in. Clin. Ther. 2003;25(3):1039.","DOI":"10.1016\/S0149-2918(02)80034-0"},{"issue":"1","key":"10.1016\/j.medmal.2006.05.009_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1378\/chest.128.1.172","article-title":"Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors","volume":"128","author":"Leroy","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.medmal.2006.05.009_bib39","first-page":"748","article-title":"Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia","volume":"16","author":"Fogarty","year":"1999","journal-title":"Infect. Med."},{"issue":"1","key":"10.1016\/j.medmal.2006.05.009_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.119.1.185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults","volume":"119","author":"Petitpretz","year":"2001","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.medmal.2006.05.009_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jemermed.2004.02.023","article-title":"Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy","volume":"27","author":"Katz","year":"2004","journal-title":"J. Emerg. Med."},{"issue":"6","key":"10.1016\/j.medmal.2006.05.009_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-005-1347-1","article-title":"Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors","volume":"24","author":"Portier","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1086\/498520","article-title":"Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy vs that of levofloxacin therapy","volume":"42","author":"Anzueto","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.medmal.2006.05.009_bib44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.medmal.2006.05.009_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Dunbar","year":"2004","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.medmal.2006.05.009_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7\u00a0day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.medmal.2006.05.009_bib47","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.medmal.2006.05.009_bib48","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin vs 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults","volume":"49","author":"D'Ignazio","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.medmal.2006.05.009_bib49","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1378\/chest.128.4.2230","article-title":"Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults","volume":"128","author":"Drehobl","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.medmal.2006.05.009_bib50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.patbio.2005.07.010","article-title":"Essai comparatif de l'efficacit\u00e9 et de la tol\u00e9rance de la pristinamycine vs amoxicilline dans le traitement des pneumonies aigu\u00ebs communautaires de l'adulte","volume":"53","author":"Tr\u00e9moli\u00e8res","year":"2005","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.medmal.2006.05.009_bib51","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib52","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/379329","article-title":"Azithromycin in the treatment of Legionella pneumonia requiring hospitalization","volume":"37","author":"Plouffe","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib53","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired legionellosis","volume":"125","author":"Yu","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.medmal.2006.05.009_bib54","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/428049","article-title":"Antimicrobial chemotherapy for legionnaires disease: levofloxacin vs macrolides","volume":"40","author":"Blazquez Garrido","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10096-004-1152-2","article-title":"Efficacy of telithromycin in community-acquired pneumonia caused by Legionella\u00a0pneumophila","volume":"23","author":"Carbon","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/00365549850160710","article-title":"A comparative study of l\u00e9vofloxacine and ceftriaxone in the treatment of hospitalized patients with pneumonia","volume":"30","author":"Norrby","year":"1998","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.medmal.2006.05.009_bib57","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/AAC.43.10.2484","article-title":"Development of new experimental model of penicillin-resistant Streptococcus\u00a0pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics","volume":"10","author":"Piroth","year":"1999","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06001375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06001375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:05:26Z","timestamp":1759971926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X06001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":57,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0399077X06001375"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2006.05.009","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumonies aigu\u00ebs communautaires\u00a0: analyse critique des\u00a0essais cliniques","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2006.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}